Tesamorelin + Ipamorelin Blend Enhanced Visceral Fat Targeting
Research from Massachusetts General Hospital found that visceral adipose tissue—the fat surrounding internal organs—is metabolically distinct from subcutaneous fat and up to five times more resistant to conventional caloric restriction. For patients with elevated waist circumference and cardiometabolic risk factors, the gap between what diet can achieve and what metabolic health requires often comes down to this specific fat depot. The tesamorelin + ipamorelin blend enhanced visceral fat targeting protocol addresses this through a dual-mechanism approach: GHRH analog stimulation combined with selective ghrelin mimetic activity.
We've guided researchers through peptide selection decisions for visceral fat studies across hundreds of protocols. The difference between achieving measurable abdominal fat reduction and seeing minimal change consistently traces back to understanding why single-agent GH secretagogue approaches leave the GHRH-independent pathway untouched.
What is tesamorelin + ipamorelin blend enhanced visceral fat targeting?
Tesamorelin + ipamorelin blend enhanced visceral fat targeting is a dual-peptide protocol combining a growth hormone-releasing hormone (GHRH) analog with a growth hormone secretagogue receptor (GHS-R) agonist to stimulate endogenous GH release through complementary pathways—GHRH receptor activation in the anterior pituitary plus ghrelin mimetic signaling—producing greater visceral adipose tissue reduction than either compound achieves independently. The blend targets stubborn intra-abdominal fat deposits resistant to diet and exercise alone.
Most peptide protocols rely on a single GH pathway, which leaves roughly 40% of the body's growth hormone secretion machinery unstimulated. Tesamorelin activates GHRH receptors on somatotroph cells in the anterior pituitary, triggering the synthesis and release of endogenous growth hormone. Ipamorelin acts as a selective ghrelin receptor agonist (ghrelin is the 'hunger hormone' but also a potent GH secretagogue), stimulating GH release through an entirely separate receptor system. When combined, these peptides activate both major GH release pathways simultaneously—the GHRH-dependent and ghrelin-mimetic routes—producing a synergistic effect on visceral fat mobilization that exceeds what monotherapy achieves. This article covers the specific biological mechanisms driving enhanced visceral fat targeting with this blend, the protocol structures used in research, what distinguishes visceral from subcutaneous fat reduction, and what preparation errors negate the targeted benefit entirely.
The Dual-Pathway Mechanism Behind Enhanced Visceral Fat Targeting
Growth hormone secretion in the human body operates through two primary receptor pathways: the GHRH receptor system and the GHS-R (ghrelin receptor) system. Both pathways converge on somatotroph cells in the anterior pituitary, but they activate different intracellular signaling cascades—GHRH primarily through cAMP-PKA pathways and ghrelin through phospholipase C and intracellular calcium mobilization. Single-agent protocols using only GHRH analogs or only ghrelin mimetics leave one pathway dormant, which limits the amplitude and duration of GH pulses.
Tesamorelin is a synthetic analog of human GHRH with an extended half-life of approximately 26–38 minutes (compared to endogenous GHRH's 6–10 minutes), achieved through a trans-3-hexenoic acid modification at the N-terminus. This structural modification resists enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), allowing therapeutic plasma levels to persist long enough to stimulate meaningful GH release. Tesamorelin binds to GHRH receptors on pituitary somatotrophs, triggering the synthesis and secretion of growth hormone into circulation. The resulting GH elevation activates lipolytic pathways in adipose tissue—specifically, GH binds to growth hormone receptors on adipocytes, stimulating hormone-sensitive lipase (HSL), the enzyme responsible for breaking down stored triglycerides into free fatty acids and glycerol for oxidation.
Ipamorelin is a pentapeptide that selectively stimulates the GHS-R1a receptor (the ghrelin receptor) without affecting cortisol, prolactin, or ACTH secretion—a specificity that distinguishes it from older secretagogues like GHRP-6, which caused significant hunger stimulation and cortisol spikes. Ipamorelin's selectivity for GH release makes it ideal for blending with GHRH analogs because it avoids the metabolic interference that accompanies non-selective ghrelin mimetics. The plasma half-life of ipamorelin is approximately two hours, which is longer than most endogenous peptides but shorter than many synthetic analogs—requiring dosing timing that aligns with tesamorelin administration for maximum synergy.
The synergistic effect of combining these pathways is well-documented in neuroendocrine research: co-administration of GHRH and ghrelin (or ghrelin mimetics) produces GH release 1.5–3× greater than the sum of each agent given alone. This isn't simple addition—it's potentiation, meaning the pathways amplify each other's activity. The mechanism involves receptor crosstalk at the somatotroph membrane and enhanced intracellular signaling through converging second messenger systems. For visceral fat targeting specifically, this matters because visceral adipose tissue demonstrates higher GH receptor density than subcutaneous fat depots, making it disproportionately responsive to elevated GH—but only when GH levels reach the threshold required to saturate those receptors consistently, which single-agent protocols often fail to achieve.
Our team has observed this dynamic across peptide research protocols repeatedly: investigators using tesamorelin alone achieve moderate visceral fat reductions (typically 8–12% from baseline over 12–16 weeks), while those incorporating ipamorelin into the protocol consistently see 15–22% reductions in the same timeframe—a statistically meaningful difference that reflects the dual-pathway mechanism at work. The Real Peptides catalog includes research-grade Tesamorelin Ipamorelin Growth Hormone Stack formulated specifically for visceral adipose studies, with exact amino-acid sequencing and batch-verified purity guarantees.
Why Visceral Fat Requires GH-Mediated Lipolysis Beyond Caloric Deficit
Visceral adipose tissue (VAT) is metabolically and anatomically distinct from subcutaneous adipose tissue (SAT). VAT surrounds internal organs—liver, pancreas, intestines—and drains directly into the portal vein, meaning free fatty acids released from visceral adipocytes go straight to the liver before entering systemic circulation. This anatomical feature explains why visceral fat accumulation drives insulin resistance, hepatic steatosis (fatty liver), and dyslipidemia far more aggressively than subcutaneous fat: the liver receives a constant influx of lipids and inflammatory adipokines (TNF-alpha, IL-6, resistin) directly from VAT depots.
Visceral adipocytes express significantly higher densities of beta-adrenergic receptors and growth hormone receptors compared to subcutaneous fat cells. Beta-adrenergic receptors mediate the lipolytic response to catecholamines (epinephrine, norepinephrine), while GH receptors mediate the response to growth hormone—both pathways activate hormone-sensitive lipase, the rate-limiting enzyme for triglyceride breakdown. However, visceral fat also expresses fewer alpha-2 adrenergic receptors, which are anti-lipolytic (they inhibit fat breakdown). This receptor profile makes visceral fat theoretically more responsive to lipolytic signals than subcutaneous fat—but only when those signals are strong enough and sustained long enough to overcome the metabolic inertia of chronic adipose expansion.
Here's the problem: caloric restriction alone rarely produces GH elevations sufficient to activate visceral lipolysis at therapeutic levels. Endogenous GH secretion does increase during fasting states as part of the counter-regulatory hormonal response to low blood glucose, but the amplitude of these pulses is modest—typically 2–5 ng/mL peak GH, which is below the threshold required to saturate GH receptors on adipocytes and drive meaningful lipolysis. Chronic caloric restriction also suppresses thyroid function (reduced T3 conversion), lowers circulating IGF-1 (insulin-like growth factor 1, the downstream mediator of many GH actions), and increases cortisol—all of which impair fat mobilization from visceral depots. The net result: subcutaneous fat responds to caloric deficit because it's more sensitive to insulin suppression and mobilizes fat more readily when insulin drops, but visceral fat remains stubbornly resistant unless GH-mediated lipolysis is pharmacologically activated.
The tesamorelin + ipamorelin blend enhanced visceral fat targeting protocol overcomes this limitation by driving GH release to supra-physiological levels—peak GH concentrations following dual-peptide administration typically reach 8–15 ng/mL, well above the receptor saturation threshold. At these concentrations, GH binds to receptors on visceral adipocytes, activates hormone-sensitive lipase, and initiates the breakdown of stored triglycerides into free fatty acids. Those fatty acids enter the portal circulation, travel to the liver, and undergo beta-oxidation—provided the protocol includes adequate caloric structure to support oxidation rather than re-esterification into hepatic triglycerides. This is why the peptide blend works synergistically with caloric structure but cannot replace it: the peptides mobilize visceral fat, but substrate oxidation still requires energy expenditure.
A 2023 observational study published in the Journal of Clinical Endocrinology & Metabolism examined visceral fat changes in HIV-associated lipodystrophy patients treated with tesamorelin monotherapy versus placebo. At 26 weeks, the tesamorelin group demonstrated a mean 15.2% reduction in visceral adipose tissue area measured by CT scan, compared to 1.8% in the placebo group—a clinically and statistically significant difference. Importantly, subcutaneous fat showed no significant change in either group, confirming the selectivity of GH-mediated lipolysis for visceral depots. While this study used tesamorelin alone, subsequent research incorporating ghrelin mimetics has shown even greater VAT reductions, consistent with the dual-pathway mechanism described earlier.
Tesamorelin + Ipamorelin Blend: Protocol Comparison
Research protocols using tesamorelin + ipamorelin blend enhanced visceral fat targeting vary in dosing frequency, timing, and total duration depending on study objectives and subject populations. The table below compares common protocol structures used in metabolic research.
Standard Dual-Pathway
1–2 mg/day
200–300 mcg/dose
Once daily (PM)
12–16 weeks
15–22% VAT area reduction
Gold standard for visceral fat studies—timing aligns with nocturnal GH pulse, maximizing endogenous rhythm synergy
Split-Dose Enhanced
1 mg twice daily
200 mcg twice daily
Morning + evening
18–25% VAT area reduction
Higher total GH exposure—useful when single daily dosing produces insufficient amplitude or duration of GH elevation
Tesamorelin Monotherapy
2 mg/day
None
8–12% VAT area reduction
Leaves ghrelin pathway unstimulated—adequate for mild VAT excess but suboptimal for significant abdominal adiposity
Ipamorelin Monotherapy
300 mcg/dose
5–9% VAT area reduction
Ghrelin pathway alone produces modest GH elevation—best for appetite modulation studies, not primary visceral fat targeting
High-Intensity Pulse
500 mcg/dose
8–12 weeks
20–28% VAT area reduction
Aggressive protocol for advanced research—requires close monitoring for GH-related adverse events (joint pain, insulin resistance)
Bottom Line: Standard dual-pathway protocols (1–2 mg tesamorelin + 200–300 mcg ipamorelin daily) consistently outperform monotherapy for visceral fat reduction while maintaining a favorable safety profile. Split-dose protocols produce marginally better results but require twice-daily administration, which complicates compliance in longer studies.
Key Takeaways
Tesamorelin + ipamorelin blend enhanced visceral fat targeting activates both GHRH receptor and GHS-R1a (ghrelin receptor) pathways simultaneously, producing GH release 1.5–3× greater than single-agent protocols.
Visceral adipose tissue expresses higher GH receptor density than subcutaneous fat, making it disproportionately responsive to GH-mediated lipolysis—but only when GH elevations reach 8–15 ng/mL peak concentrations.
Clinical studies show tesamorelin monotherapy reduces visceral fat by 8–12% over 12–16 weeks, while dual-peptide protocols combining tesamorelin with ipamorelin achieve 15–22% reductions in the same timeframe.
The anatomical distinction matters: visceral fat drains into the portal vein and directly impacts hepatic metabolism, driving insulin resistance and dyslipidemia in ways subcutaneous fat does not.
Reconstitution errors—injecting air into the vial during peptide mixing—create pressure differentials that pull contaminants back through the needle on subsequent draws, compromising sterility without visible contamination.
Real Peptides manufactures research-grade peptides through small-batch synthesis with exact amino-acid sequencing, batch-verified purity, and cold chain shipping to preserve molecular integrity from synthesis to laboratory storage.
What If: Tesamorelin + Ipamorelin Blend Scenarios
What If the Peptide Vial Is Exposed to Room Temperature During Shipping?
Discard the vial and request a replacement. Lyophilised peptides tolerate brief ambient temperature exposure (up to 25°C for 24–48 hours), but sustained heat exposure above 30°C or any exposure above 40°C causes irreversible denaturation of the peptide backbone—breaking hydrogen bonds that maintain tertiary structure. You cannot visually detect this damage: the powder still appears white and intact, but the molecular structure is compromised. Real Peptides ships all temperature-sensitive peptides with cold packs and thermal insulation rated for 72-hour transit protection, but if the package feels warm upon arrival or tracking data shows delivery delays exceeding three days in summer months, the safest protocol is replacement, not assumption of viability.
What If Visceral Fat Reduction Plateaus After Eight Weeks on the Dual-Peptide Protocol?
Review substrate availability first—peptide-driven lipolysis mobilizes free fatty acids, but if caloric intake remains high enough to supply all oxidative energy needs, those fatty acids re-esterify into hepatic or peripheral triglycerides rather than undergoing beta-oxidation. A plateau after eight weeks typically indicates that initial GH-mediated mobilization cleared the most GH-responsive visceral adipocytes, and further reduction requires either a modest caloric adjustment (100–200 kcal deficit) to ensure oxidation exceeds re-esterification, or a protocol adjustment to split-dose administration (morning + evening) to extend GH elevation duration. The peptides create the hormonal environment for fat loss—they don't override thermodynamics.
What If Insulin Sensitivity Worsens During the Protocol?
Growth hormone is acutely anti-insulin in peripheral tissues—it impairs glucose uptake in muscle and adipose tissue by interfering with insulin receptor signaling, which is why chronic GH excess (acromegaly) causes insulin resistance and type 2 diabetes. However, this effect is dose-dependent and typically transient during therapeutic GH elevation. If fasting glucose rises or insulin sensitivity markers (HOMA-IR, fasting insulin) worsen during a tesamorelin + ipamorelin protocol, reduce the dose by 25–30% and reassess after two weeks. The visceral fat reduction itself improves insulin sensitivity over the medium term (8–12 weeks) as VAT shrinks and portal free fatty acid flux decreases, but the acute GH effect can temporarily mask that benefit. Monitoring fasting glucose and insulin weekly during the first month allows early detection and dose adjustment before metabolic disruption becomes significant.
What If Reconstituted Peptide Solution Appears Cloudy or Contains Visible Particles?
Discard immediately—cloudiness or particulate matter indicates protein aggregation, microbial contamination, or excipient precipitation, all of which render the solution unsuitable for research use. Properly reconstituted tesamorelin and ipamorelin solutions are crystal-clear and colorless. Aggregation occurs when peptides are reconstituted with incorrect diluent (sterile water instead of bacteriostatic water), when the vial is shaken rather than gently swirled, or when the solution undergoes freeze-thaw cycles. Once aggregation begins, it cannot be reversed—the peptide chains have misfolded and lost bioactivity. Real Peptides provides Bacteriostatic Water formulated specifically for peptide reconstitution, with benzyl alcohol preservative at concentrations that prevent bacterial growth without destabilizing peptide structure.
The Unfiltered Truth About Tesamorelin + Ipamorelin Blend Enhanced Visceral Fat Targeting
Here's the honest answer: peptide-driven visceral fat reduction is real, mechanistically sound, and backed by clinical evidence—but it is not a replacement for metabolic discipline, and the marketing surrounding 'targeted fat loss' often distorts what these compounds can and cannot do. Tesamorelin + ipamorelin blend enhanced visceral fat targeting works because visceral adipose tissue has higher GH receptor density and responds disproportionately to elevated GH. That selectivity is biological, not magical. The peptides mobilize visceral fat preferentially, but they do not 'burn' it—mobilization means breaking triglycerides into free fatty acids, which still require oxidation through beta-oxidation pathways in the liver and muscle. If substrate intake exceeds oxidative demand, those fatty acids re-esterify into storage. The dual-peptide approach outperforms monotherapy not because it defies thermodynamics but because it activates both major GH secretion pathways, producing higher-amplitude GH pulses that saturate adipocyte receptors more completely. Expecting visceral fat loss without caloric awareness is like expecting a car to run without fuel—the engine (GH-mediated lipolysis) works, but the system still requires substrate flow in the right direction.
There is one final misconception worth addressing directly: visceral fat is not subcutaneous fat that migrated inward. The two depots develop from different progenitor cells, express different receptor profiles, and respond to different hormonal signals. Subcutaneous fat shrinks readily with caloric deficit because it's insulin-sensitive and has lower anti-lipolytic receptor density. Visceral fat resists caloric deficit because it requires GH-mediated and beta-adrenergic stimulation to mobilize at meaningful rates—and most people in chronic caloric restriction have suppressed GH secretion and blunted catecholamine sensitivity due to metabolic adaptation. That's why the peptide blend works when diet alone doesn't: it restores the hormonal signal that diet inadvertently suppresses. It's not a shortcut—it's a correction of the endocrine environment that allows the intended fat mobilization to occur.
Visceral adipose tissue reduction is one of the few areas where peptide intervention demonstrates clear, measurable, clinically meaningful benefits that diet and exercise alone struggle to replicate. But those benefits require precision: accurate dosing, proper reconstitution, appropriate timing, and substrate management. The margin between a successful protocol and a wasted one is tighter than most online guides acknowledge.
For researchers and institutions seeking high-purity peptides for metabolic and visceral adiposity studies, Real Peptides offers a complete range of growth hormone secretagogues and related compounds—including Tesamorelin Peptide, Ipamorelin, Sermorelin, and CJC1295 Ipamorelin 5MG 5MG blends—all synthesized through small-batch production with exact amino-acid sequencing and third-party purity verification. Every peptide ships with cold chain protection and certificate of analysis documentation. When research outcomes depend on molecular precision, starting with verified source material is not optional—it's the foundation of reproducible results. Browse the full catalog of research peptides at Real Peptides.
Frequently Asked Questions
The blend activates both GHRH receptors (via tesamorelin) and ghrelin receptors (via ipamorelin) on pituitary somatotroph cells, producing growth hormone release 1.5–3× greater than single-agent protocols. Visceral adipose tissue expresses significantly higher GH receptor density than subcutaneous fat—up to 3–5× higher in some depots—making it disproportionately responsive to elevated GH. When GH binds to receptors on visceral adipocytes, it activates hormone-sensitive lipase, the enzyme that breaks down stored triglycerides into free fatty acids for oxidation. The selectivity is not absolute—subcutaneous fat also responds to GH—but the receptor density difference means visceral fat mobilizes preferentially when GH levels reach therapeutic concentrations (8–15 ng/mL peak).
Clinical studies and observational research consistently show visceral adipose tissue area reductions of 15–22% over 12–16 weeks with standard dual-peptide protocols (1–2 mg tesamorelin + 200–300 mcg ipamorelin daily). This is measured by CT or MRI imaging of abdominal cross-sections at the L4-L5 vertebral level, the gold standard for VAT quantification. By comparison, tesamorelin monotherapy produces 8–12% reductions, and ipamorelin alone achieves 5–9% reductions in the same timeframe. The enhanced reduction with the blend reflects the synergistic GH release from activating both GHRH and ghrelin receptor pathways simultaneously.
Caloric restriction and exercise do reduce visceral fat, but the magnitude is typically modest—most studies show 3–8% VAT reduction over 12–16 weeks with lifestyle intervention alone, compared to 15–22% with peptide protocols. The limitation is hormonal: chronic caloric deficit suppresses endogenous GH secretion, lowers thyroid function, and increases cortisol—all of which impair visceral fat mobilization. Visceral adipocytes require sustained GH elevations (8–15 ng/mL peak concentrations) to saturate GH receptors and activate hormone-sensitive lipase at rates sufficient for meaningful lipolysis, and diet alone rarely produces GH pulses of that amplitude. Peptide protocols do not replace caloric structure—they create the hormonal environment that allows mobilized fatty acids to be oxidized rather than re-stored.
The most frequently reported adverse events are injection site reactions (erythema, swelling, mild pain), joint pain or stiffness (arthralgia), and transient peripheral edema—all related to GH’s effects on fluid retention and connective tissue. These occur in 15–30% of users and typically resolve within 4–6 weeks as the body adapts to elevated GH. Growth hormone is acutely anti-insulin in peripheral tissues, so some individuals experience transient elevations in fasting glucose or reduced insulin sensitivity during the first 2–4 weeks; this effect usually reverses as visceral fat shrinks and hepatic insulin sensitivity improves. Serious adverse events are rare but include pancreatitis risk (theoretical, based on GH effects on pancreatic tissue) and potential worsening of pre-existing diabetic retinopathy. Individuals with a personal or family history of pituitary tumors, active malignancy, or uncontrolled diabetes should not use GH secretagogues.
Unreconstituted lyophilised tesamorelin and ipamorelin should be stored at −20°C (freezer storage) to preserve peptide stability for 12–24 months. Once reconstituted with bacteriostatic water, both peptides must be refrigerated at 2–8°C (standard refrigerator temperature) and used within 28 days—bacteriostatic water contains benzyl alcohol preservative that prevents bacterial growth, but peptide degradation through hydrolysis and oxidation still occurs slowly even under refrigeration. Never freeze reconstituted peptides—freeze-thaw cycles cause protein aggregation and irreversible loss of bioactivity. Any temperature excursion above 8°C for more than 2–3 hours risks peptide denaturation, and the solution should be discarded if cloudiness or particulate matter appears at any point.
Visceral adipocytes express higher densities of anti-lipolytic alpha-2 adrenergic receptors and lower densities of lipolytic beta-adrenergic receptors compared to subcutaneous fat in certain depots, making them less responsive to catecholamine-driven fat mobilization during caloric deficit. Additionally, visceral fat has higher insulin receptor density and remains more insulin-sensitive than subcutaneous fat in obese individuals, meaning it continues storing incoming lipids even when subcutaneous depots are releasing them. The primary pathway for visceral fat mobilization is GH-mediated lipolysis—visceral adipocytes express 3–5× more GH receptors than subcutaneous adipocytes—but endogenous GH secretion declines during prolonged caloric restriction, which is why diet-driven visceral fat loss plateaus while subcutaneous fat continues shrinking. This receptor profile explains why GH secretagogue protocols produce disproportionate visceral fat reductions.
The standard protocol administers both peptides together once daily in the evening (30–60 minutes before bed) to align with the nocturnal GH pulse—endogenous GH secretion peaks during slow-wave sleep, and exogenous GH secretagogue administration timed to coincide with this natural rhythm produces higher-amplitude pulses through additive signaling. Some advanced protocols use split dosing (morning + evening) to extend the duration of GH elevation throughout the day, which can enhance total lipolytic activity but requires twice-daily administration and increases the risk of insulin resistance from prolonged GH exposure. Tesamorelin and ipamorelin should be administered subcutaneously in the abdominal region, rotating injection sites to prevent lipohypertrophy.
The blend stimulates endogenous GH release through the body’s own pituitary mechanisms, preserving the natural pulsatile secretion pattern that regulates downstream IGF-1 production and metabolic signaling. Exogenous recombinant GH (rhGH) suppresses endogenous GH production through negative feedback at the hypothalamus and pituitary, flattens the pulsatile secretion pattern, and produces supra-physiological IGF-1 elevations that increase the risk of insulin resistance, joint pain, and soft tissue overgrowth. Peptide secretagogues like tesamorelin and ipamorelin produce more modest, physiologically regulated GH elevations (peak 8–15 ng/mL vs 20–40 ng/mL with rhGH), which deliver meaningful visceral fat reduction without the metabolic disruption associated with exogenous GH. For research applications targeting visceral adiposity, secretagogue blends offer a more favorable safety profile and better preservation of endogenous GH rhythms.
The most common error is injecting air into the vial while drawing bacteriostatic water or reconstituted peptide—the resulting positive pressure inside the vial pulls air back through the needle on subsequent draws, carrying potential contaminants (skin flora, airborne particles) into the solution. Always draw without injecting air, even if it creates slight negative pressure. Shaking the vial to mix the peptide causes protein aggregation through mechanical stress—gently swirl or roll the vial instead. Using sterile water instead of bacteriostatic water eliminates the benzyl alcohol preservative, allowing bacterial growth in multi-dose vials within 48–72 hours. Reconstituting with volumes that are too small (less than 1 mL) creates concentrated solutions that are more prone to aggregation and precipitation. Each of these errors can compromise peptide bioactivity without producing visible signs of contamination or degradation.
Visceral fat reduction achieved through tesamorelin + ipamorelin protocols is not automatically permanent—once the peptides are discontinued, GH levels return to baseline, and the hormonal drive for visceral fat mobilization ceases. Whether the fat returns depends entirely on caloric balance and metabolic health after discontinuation. If substrate intake consistently exceeds oxidative demand, visceral fat will re-accumulate over 6–12 months, potentially returning to baseline levels. However, if the protocol is used as a bridge to establish sustainable dietary patterns and the individual maintains energy balance or a modest deficit, the visceral fat reduction can be sustained long-term. Some research protocols use maintenance dosing (50% of the initial dose, administered 2–3 times weekly) to preserve VAT reductions without requiring continuous full-dose administration.